Yeran Li
0000-0002-9777-7152
Publication & Citation Trends
Most Cited Works
Publications
64 total
Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Cited by 5
Semantic Scholar
Efficacy analysis of multidisciplinary treatment for Wilms tumor in a single center OA
Cited by 3
Semantic Scholar
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices PDF
Cited by 24
OpenAlex
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data PDF
Cited by 24
OpenAlex
Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.
Cited by 6
Semantic Scholar
Corrigendum to "Adjuvant and first line chemotherapy use for endometrial cancer" [Gynecol. Oncol. Rep. 41 (2022) 101002]. OA
Cited by 0
Semantic Scholar
Patterns of chemotherapy use in women with recurrent endometrial cancer (582)
Cited by 0
Semantic Scholar
Adjuvant and first line chemotherapy use for endometrial cancer OA
Cited by 14
Semantic Scholar
Long-term survival in newly-diagnosed ovarian cancer patients.
Cited by 1
Semantic Scholar
Research Topics
Genomics and Chromatin Dynamics
(10)
Orthopaedic implants and arthroplasty
(9)
Endometrial and Cervical Cancer Treatments
(9)
Total Knee Arthroplasty Outcomes
(7)
Ovarian cancer diagnosis and treatment
(5)
Frequent Co-Authors
Affiliations
Huaqiao University
Merck & Co., Inc., Rahway, NJ, USA (United States)
Harvard University
Deakin University
Iowa State University